Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Psychedelic Drugs

New study sheds light on which post-psychedelic difficulties last longest and what helps people cope

by Eric W. Dolan
May 18, 2025
in Psychedelic Drugs
[PsyPost]

[PsyPost]

Share on TwitterShare on Facebook
Don't miss out! Follow PsyPost on Bluesky!

While psychedelics are gaining attention for their therapeutic potential, some users report lingering psychological difficulties that extend well beyond the immediate effects of the drug. A new study published in the Journal of Psychedelic Studies provides one of the most detailed assessments to date of these long-term challenges, examining their prevalence, severity, duration, and the coping strategies people find most effective. The findings suggest that while anxiety and panic are among the most disruptive, issues like existential struggle and diminished self-esteem tend to last the longest—often persisting for over a year.

Psychedelics like psilocybin, LSD, and ayahuasca have shown promise in treating mental health conditions, but not all outcomes are positive. A significant minority of users report psychological disturbances that linger beyond the acute effects of the drug. Previous studies have found that around 5% to 25% of users experience such issues, and some continue to struggle for months or even years.

These difficulties can include anxiety, perceptual changes, depression, confusion, and existential distress. While many users continue to view their psychedelic experiences positively, researchers have called for a more nuanced understanding of the risks involved and how people recover from negative effects.

“I am part of the Challenging Psychedelic Experiences research team, and we have been exploring adverse reactions to psychedelics across a series of research studies since 2023,” said study author Oliver C. Robinson, an associate professor of psychology at the University of Greenwich.

“While research shows that the majority benefit from the clinical or guided use of psychedelics, a minority have adverse reactions. These emotional or behavioral difficulties have been largely overlooked in research studies that have primarily focused on the average positive effects among users.”

To address this gap, the present study set out to identify which post-psychedelic difficulties are most common, how severe and long-lasting they are, and what strategies help people manage them. The researchers hypothesized that different types of difficulties would vary in severity and duration, and that people would use different coping strategies depending on the nature of the problem.

The study involved an online survey of 159 adults who had experienced psychological difficulties lasting more than one day after using a psychedelic drug between 2 and 10 years ago. Participants were recruited through newsletters, social media, and previous studies. The sample included individuals from North America and Europe, most of whom had high levels of education. Participants were asked to focus on one specific psychedelic experience that had led to lasting challenges and completed detailed assessments of the difficulties they encountered.

Participants reported whether they had experienced any of 11 different types of psychological difficulties, such as anxiety, depression, social disconnection, existential struggle, derealization, and paranoia. They rated the severity of each difficulty on a three-point scale and indicated how long each issue persisted. The researchers also asked participants to select up to two coping strategies that had helped them manage each difficulty. Options ranged from professional therapy and support from friends and family to self-education, meditation, physical activity, and breathing techniques.

The most frequently reported difficulties were social disconnection (72%), anxiety and panic attacks (68%), and existential struggle (65%). More than half of participants also reported depression (61%) and derealization (55%). Less common were paranoia and visual disturbances, each affecting about 21% of the sample.

In terms of severity, anxiety and panic attacks were rated as the most disruptive to daily life, followed by paranoia and difficulty thinking clearly. In contrast, depersonalization, derealization, and visual disturbances were rated as less severe on average. Although many participants experienced these perceptual or dissociative symptoms, they tended to interfere less with daily functioning compared to emotional or cognitive issues.

When looking at duration, existential struggle and diminished self-esteem stood out as the longest-lasting challenges. Both persisted on average for more than 15 months—significantly longer than other issues like anxiety or depression. These findings align with earlier research showing that some individuals find it difficult to integrate profound or disorienting psychedelic experiences, particularly those involving shifts in their worldview or sense of identity.

The findings highlight “that some people who take psychedelics experience disorienting and disruptive difficulties pertaining to emotions, their sense of self or even sense of reality that can last for weeks or months,” Robinson told PsyPost.

The study also revealed which coping strategies were perceived as most helpful for each type of difficulty. Self-education—such as reading or watching videos to better understand one’s experience—was the most frequently cited strategy overall. It was especially helpful for managing existential struggle, social disconnection, derealization, and visual disturbances.

Professional therapy was most commonly used for depression and diminished self-esteem, suggesting that these issues often require more structured support. Support from peers and family was rated as most effective for anxiety and panic attacks, underscoring the importance of interpersonal connection in the recovery process.

“It surprised me that more people find chatting with peers to be effective than chatting with therapists,” Robinson said. “It may be that therapists are not yet well trained to handle the conundrum of working with psychedelics and associated difficulties.”

Some challenges, including depersonalization, sleep problems, and cognitive confusion, did not show strong preferences for specific coping strategies, suggesting that these may be more variable in how people manage them. In general, though, the study found that different problems call for different types of support.

These results have several implications. First, they show that extended difficulties following psychedelic use are not only common but also diverse in form and duration. Second, they suggest that coping with these difficulties is not a one-size-fits-all process. People benefit from a range of strategies, from reading and journaling to therapy and social support. Third, the findings highlight gaps in current systems of care. Many people rely on self-guided learning or informal peer networks rather than professional help, possibly because psychedelic integration is still a niche area within mainstream mental health services.

The researchers acknowledge some limitations. The data were collected retrospectively, which introduces the possibility of memory bias. People may not accurately recall the timeline of their symptoms or what helped them recover. The sample also skewed toward educated individuals from Western countries, which may not reflect the full range of experiences across different cultural or socioeconomic backgrounds.

“This is a sample mainly from the United Kingdom and the United States,” Robinson noted. “In countries where there is a legal psychedelic culture, such as Brazil or Peru, we would expect very different results.”

Future research could address these limitations by tracking individuals in real time, starting before they use psychedelics and following up afterward to assess both short- and long-term outcomes. Cross-cultural studies could also shed light on how different settings, belief systems, and social supports shape the experience and aftermath of psychedelic use. It may also be helpful to explore the biological underpinnings of persistent symptoms, particularly those involving perception or cognition.

“We are currently exploring how individuals who have childhood trauma and then take psychedelics experience the resolution, or exacerbation, of the early trauma,” Robinson said. “We are also involved in a Global Psychedelic Survey that will bring data on how common adverse reactions to psychedelics are.”

“We find that even among people who have difficulties after psychedelic usage, the vast majority retain a favorable view of psychedelics as agents of positive change,” he added. “This shows that perhaps the difficulties relate to issues that, once made conscious, can be resolved to some degree. This process may be distressing, but we see a similar pattern with extended psychotherapy—people tend to get worse before they get better.”

The study, “An investigation into the varieties of extended difficulties following psychedelic drug use: Duration, severity and helpful coping strategies,” was authored by Oliver C. Robinson, Jules Evans, Rosalind G. McAlpine, Eirini K. Argyri, and David Luke.

TweetSendScanShareSendPin1ShareShareShareShareShare

RELATED

Psychedelic use linked to increased risk of unusual visual experiences
Ayahuasca

Study links moderate awe in psychedelic ayahuasca journeys to better well-being

June 21, 2025

A new study published in the Journal of Psychoactive Drugs suggests that while awe can be transformative during ayahuasca retreats, there’s a limit. Experiences marked by excessive vastness were linked to lower well-being, challenging assumptions about awe’s universal benefits.

Read moreDetails
About 8% of psychedelic users report inappropriate sexual contact by guides
Psychedelic Drugs

Study links psychedelic use in illegal settings to increased psychotic and manic symptoms

June 18, 2025

New research suggests that naturalistic psychedelic use may worsen psychotic and manic symptoms when used in illegal settings. People with schizophrenia or bipolar I disorder appeared especially vulnerable to these effects, highlighting the importance of context and psychiatric background.

Read moreDetails
Some dark personality traits may help buffer against depression, new psychology research suggests
Mental Health

Psilocybin-assisted therapy linked to reduced depression in people with bipolar disorder, small study finds

June 17, 2025

A pilot study involving psilocybin-assisted therapy found possible antidepressant effects for people with bipolar II disorder. The treatment appeared well-tolerated, with no signs of mania or psychosis, offering cautious optimism for future bipolar depression research.

Read moreDetails
Psilocybin from “magic” mushrooms weakens the brain’s response to angry faces
Addiction

Single-dose psilocybin therapy shows promise for reducing alcohol consumption

June 15, 2025

Early results from a pilot study indicate that psilocybin-assisted therapy could be linked to lower alcohol consumption and improved psychological outcomes, though larger controlled trials are needed to determine whether the psilocybin itself is responsible for these changes.

Read moreDetails
Psilocybin appears to have a uniquely powerful relationship with nature relatedness
Neuroimaging

Psilocybin induces large-scale brain network reorganization, offering insights into the psychedelic state

June 14, 2025

A new study using high-resolution EEG reveals that psilocybin dramatically alters brain connectivity in rats. The psychedelic induced dose-dependent changes in network organization, disrupting normal patterns of neural communication and suggesting rodents may be viable models for studying altered consciousness.

Read moreDetails
Brain chemistry imbalance revealed in violent offenders with antisocial personality disorder
LSD

Flipping two atoms in LSD turned it into a powerful treatment for damaged brain circuits

June 13, 2025

A new study introduces JRT, a modified version of LSD that promotes brain cell growth without triggering hallucinations. Researchers say this non-hallucinogenic compound could offer safer treatment options for schizophrenia and related brain disorders where psychedelics are typically contraindicated.

Read moreDetails
Brain connectivity maps shed light on the synergistic effects of meditation and psilocybin
Psychedelic Drugs

Psychedelic experiences can both cause and resolve spiritual struggles, study suggests

June 12, 2025

A new study has found that people frequently described both relief from spiritual tension and the emergence of new spiritual struggles following psychedelic use.

Read moreDetails
Meta-analysis highlights potential of psilocybin therapy for treatment-resistant depression
Depression

Psilocybin therapy shows similar benefits for patients with and without recent antidepressant use

June 11, 2025

A new study finds that individuals with treatment-resistant depression experienced similar improvements from psilocybin-assisted psychotherapy whether or not they had recently discontinued antidepressant medications.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Exposure to heavy metals is associated with higher likelihood of ADHD diagnosis

Eye-tracking study shows people fixate longer on female aggressors than male ones

Romantic breakups follow a two-stage decline that begins years before the split, study finds

Believing “news will find me” is linked to sharing fake news, study finds

A common parasite not only invades the brain — it can also decapitate human sperm

Almost all unmarried pregant women say that the fetus resembles the father, study finds

New neuroscience research reveals brain antioxidant deficit in depression

Scientists uncover kidney-to-brain route for Parkinson’s-related protein spread

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy